tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Integral Diagnostics Issues New Performance Rights

Story Highlights
Integral Diagnostics Issues New Performance Rights

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Integral Diagnostics Ltd. ( (AU:IDX) ).

Integral Diagnostics Ltd. announced the issuance of 214,921 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until these restrictions are lifted, potentially impacting employee retention and motivation.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

More about Integral Diagnostics Ltd.

Integral Diagnostics Ltd. operates in the healthcare industry, providing diagnostic imaging services. The company focuses on delivering high-quality radiology services across various regions, utilizing advanced technology and a skilled workforce to meet the needs of patients and healthcare providers.

Average Trading Volume: 1,063,185

Technical Sentiment Signal: Buy

Current Market Cap: A$1.01B

Find detailed analytics on IDX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1